Efficacy of intravenous moxifloxacin in treating patients with moderate to severe community-acquired pneumonia

Chinese Journal of Infection and Chemotherapy

Volumn 6, Issue 5, 2006, Pages 296-300

  Zhang, Wen Hui ^a   Zhu, Shu Yang ^a   Chen, Hao ^a   Zhang, Zhi Liang ^a   Zhang, Ye Qing ^a   Shao, Hua Jun ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Community acquired; Fluoroquinolone; Pneumonia; Treatment

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS SULBACTAM; AZITHROMYCIN; CEFOPERAZONE; CEFTAZIDIME; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

EID: 33750344233     PISSN: 10097708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia[J]. Clin Ther, 1998, 20:820-837.
2. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines [J]. Thorax, 2001,56:296-301.
3. Dudas V, Hopefl A, Jacobs R, et al. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of non teaching US community hospitals [J]. Ann Pharmacother, 2000,34:446-452.
4. Chinese source. 1999,22:199-201.
5. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low risk patients with community acquired pneumonia [J]. N Engl J Med, 1997,336:243-250.
6. Chinese source. 2004,27:155-160.
7. Song JH, Chang HH, Suh JY, et al. Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP) [J]. J Antimicrob Chemother, 2004,53:457-463.
8. Ball P, Baquero F, Cars O, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence[J]. J Antimicrob Chemother,2002,49:31-40.
9. Hansen GT, Metzler K, Drlica K, et al. Mutant prevention concentration of gemifloxacin for clinical isolates of streptococcus pneumoniae [J]. Antimicrob Agents Chemother, 2003,47:440-441.
10. Piddock LJ. Mechanisms of fluoroquinolone resistance: an update 1994-1998[J]. Drugs,1999,58(suppl 2): 11-18.
11. Dovern GV. Antimicrobial use and the emergence of antimicrobial resistance with streptococcus pneumoniae in the United States[J]. Clin Infect Dis,2001,33(suppl 3):S187-192.
12. Dolhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolo[J]. Chemotherapy, 1996,42:410-425.
13. Andrews JM, Honeybourne D, Jevons G, et al. Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre optic bronchoscopy[J]. J Antimicrob Chemother, 1997,40:573-577.
14. Soman A, Honeybourne D, Andrews J, et al. Concentrations moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibreoptic bronchoscopy[J]. J Antimicrob Chemother, 1999,44: 835-838.
15. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the Management of Adults with Commnuity-acquired Pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention [J]. Am J Respir Crit Care Med, 2001,163:1730-1754.